Gene therapy of surfactant protein B deficiency

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 5, 2006, Pages 432-438

  Aneja, Manish Kumar ^a   Rudolph, Carsten ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Gene therapy; Non viral vector; SP B; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; ARTIFICIAL LUNG SURFACTANT; INTEGRASE; LENTIVIRUS VECTOR; LIPOSOME; NAKED DNA; POLYAMIDOAMINE; POLYETHYLENEIMINE; POLYLYSINE; RETROVIRUS VECTOR; SURFACTANT PROTEIN B; VIRUS VECTOR; ZINC FINGER PROTEIN;

DISEASE MODEL; GENE EXPRESSION; GENE THERAPY; HEREDITY; HERPES SIMPLEX VIRUS; HUMAN; LUNG ALVEOLUS CELL TYPE 2; LUNG INSUFFICIENCY; LUNG TRANSPLANTATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERINATAL PERIOD; PROTEIN DEFICIENCY; REVIEW; SURVIVAL RATE; TRANSGENIC MOUSE; TRANSPOSON; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MODELS, BIOLOGICAL; PULMONARY SURFACTANT-ASSOCIATED PROTEIN B;

ANIMALIA; MUS MUSCULUS;

EID: 33749998114     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Lee TWR, Matthews DA, Blair GE: Novel molecular approaches to cystic fibrosis gone therapy. Biochem J (2005) 387(1):1-15.
2. O'Reilly MA, Weaver TE, Pilot-Matias TJ, Sarin VK, Gazdar AF, Whitsett JA: In vitro translation, posttranslational processing and secretion of pulmonary surfactant protein B precursors. Biochim Biophys Acta (1989) 1011(2-3):140-148.
3. Hamvas A, Nogee LM, Mallory GB, Spray TL, Huddleston CB, August A, Dehner LP, deMello DE, Moxley M, Nelson R, Cole FS et al: Lung transplantation for treatment of Infants with surfactant protein B deficiency. J Pediatr (1997) 130(2):231-239.
4. Clark JC, Wert SE, Bachurski CJ, Stahiman MT, Stripp, BR, Weaver TE, Whitsett JA: Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc Natl Acad Sci USA (1995) 92(17):7794-7798.
5. Nogee LM: Genetic mechanisms of surfactant deficiency. Biol Neonate (2004) 85(4):314-318.
6. Dunbar AE III, Wert SE, Ikegami M, Whitsett JA, Hamvas A, White FV, Piedboeuf B, Jobin C, Guttentag S, Nogee LM: Prolonged survival in hereditary surfactant protein B (SP-B) deficiency associated with a novel splicing mutation. Pediatr Res (2000) 48(3)275-282
7. Yusen, RD, Cohen, AH, Hamvas, A: Normal lung function in subjects heterozygous for surfactant protein-B deficiency. Am J Respir Crit Care Med (11999) 159(2):411-414.
8. Blaese RM, Culver KW, Miller AD, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev, P, Greenblatt JJ, Rosenberg SA et al: T lymphocyte-directed gone therapy for ADA-SCID: Initial trial results after 4 years. Science (1995) 270(5235):475-480.
9. Goldman MJ, Lee PS, Yang JS, Wilson JM: Lentiviral vectors for gene therapy of cystic fibrosis. Hum Gene Ther (1997) 8(18):2261-2268.
10. Wang GSV, Zabner J, Keshavjee S, Johnston JC, Sauter SL, Jolly DJ, Dubensky TW Jr, Davidson BL, McCray PB Jr: Feline immunodeficiency virus vectors persistently transduce non-dividing airway epithelia and correct the cystic fibrosis defect J Clin Invest (1999) 104(11): R55-62.
11. Kobinger GP, Schumer GP, Medina MF, Weiner DJ, Wilson JM: Stable and efficient gene transfer in airway of non-human primates with HIV vector pseudotyped with deletion mutant of Ebola envelope glycoproteins. Pediatr Pulmonol Suppl (2003) 25:Abs 209.
12. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R et al: LMO2-associated clonal T-cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 302(5644):415-419.
13. Grubb BR, Pickles RJ, Ye H, Yankaskas JR, Vick RN, Engelhardt JF, Wilson JM, Johnson LG, Boucher RC: Inefficient gene transfer of adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature (1994) 371(6500):802-806.
14. Pickles RJ, Fahmer JA Petrella JM, Boucher, RC, Bergelson JM: Retargeting the coxsacklevirus and adenovirus receptor to the apical surface of polarised epithelial cells reveals the glycocalyx as a barrier to adenovirus mediated gene transfer. J Virol (2000) 74(13):6050-6057.
15. Walters, RW, Grunst, T, Bergelson, JM, Finberg, RW, Welsh, MJ, Zabner J: Basolateral localization of fiber receptors limits adenovirus infection from the apleall surface of airway epithelia. J Biol Chem (1999) 274(15):10219-10226.
16. Korst RJ, Bewig B, Crystal RG: In vitro and in vivo transfer and expression of human surfactant SP-A- and SP-B-associated protein cDNAs mediated by replication deficient, recombinant adenoviral vectors. Hum Gene Ther (1995) 6(3):277-287.
17. Orgall S, Wolff G, Falck-Pedersen E, Crystal RG: Innate Immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther (1997) 8(1):37-44.
18. Yang Y, Wilson JM: Clearance of adenovirus-infected hepatocytes by MHC class I restricted CD4+ CTLs in vivo. J Immmunol (1995) 155(5):2564-2569.
19. Armentano D, Zabner J, Sacks C, Sookdeo CC, Smith MP, St George JA Wadsworth SC, Smith AE, Gregory RJ: Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol (1997) 71(3):2408-2416.
20. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, Graham FL, Beaudet AL, Kochanek S: Genomic DNA transfer with a high capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet (1998) 18(3):180-183.
21. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, McLaughlin S, Muzyczka N, Rocchi M, Berns KI: Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA (1990) 87(6):2211-2215.
22. Rutledge EA, Russell DW. Adeno-associated virus integration junctions. J Virol (1997) 71(11):8429-8436
23. Smith AE: Viral vectors in gone therapy. Annu Rev Microbiol (1995) 49:807-838.
24. Flotte TR: Adeno-associated virus-mediated gene transfer for lung diseases. Hum Gene Ther (2005) 16(6):643-648.
25. Losardo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, Schatz RA, Asahara T, Isner JM, Kuntz RE: Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischaemia. Circulation (2002) 105(17):2012-2018.
26. Simovic D, Isner JM, Ropper AH, Pieczek A, Wainberg DH: Improvement in chronic Ischaemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischaemia. Arch Neurol (2001) 68(5):761-788.
27. Zabner J, Cheng SH, Meeker D, Launspach J, Balfour R, Perricone MA, Morris JE, Marshall J, Fasbender A, Smith AE, Welsh MJ: Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J Clin Invest (1997) 100(6):1529-1537.
28. Parker AL, Newman C, Briggs S, Seymour L, Sheridan PJ: Nonviral gene delivery: Techniques and implications for molecular medicine. Expert Rev Mol Med (2003) 5:1-15.
29. Oudrhiri N, Vigneron JP, Peuchmaur M, Leclerc T, Lehn JM, Lehn P: Gene transfer by guanidinium-cholosterol cationic lipids into airway epithelial cells in vitro and in vivo. Proc Natl Acad Sci USA (1997) 94(5):1651-1656.
30. Guillaume-Gable C, Floch V, Mercier B, Audrezet MP, Gobin E, Le Bolch G, Yaouanc JJ, Clement JC, des Abbayes H, Leroy JP, Morin V et al: Cationic phosphonolipids as nonvirall gene transfer agents in the lungs of mice. Hum Gene Ther (1998) 9(16):2309-2319.
31. Noone PG, Hohneker KW, Zhou Z, Johnson LG, Foy C, Gipson C, Jones K, Noah TL, Leigh MW, Schwartybach C, Efthimiou J et al: Safety and biological efficacy of a Lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol Ther (2000) 1(1):105-114.
32. Ruiz FE, Clancy JP, Perricone MA, Bebok Z, Hong JS, Cheng SH, Meeker DP, Young KR, Schoumacher RA, Weatherly MR, Wing L et al: A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum Gene Ther (2001) 12(7):751-761.
33. Urtti A, Polansky J, Lui GM, Szoka FC: Gene delivery and expression in human retinal pigment epithelial cells: Effects of synthetic carriers, serum, extracellular matrix and viral promoters. J Drug Target (2000) 7(6):413-421.
34. Zelphati O, Nguyen C, Ferrari M, Felgner J, Tsai Y, Felgner PL: Stable and monodisperse lipoplex formulations for gene delivery. Gene Ther (1998) 5(9):1272-1282.
35. Stavridis JC, Deliconstantinos G, Psallidopoulos MC, Armenakas NS, Hadjiminas DJ, Hadjiminas J: Construction of transferrin-coated liposomes for in vivo transport of exogenous DNA to bone marrow erythroblasts in rabbits. Exp Cell Res (1986) 164(2):568-572.
36. Dzau JV, Mann MJ, Morishita R, Kaneda Y: Fusigenic viral liposome for gene therapy in cardiovascular disease. Proc Natl Acad Sci USA (1998) 93(21):11421-11425.
37. Boussif O, Lezoualc'h F, Zanta MA, Mergny M, Scherman D, Demeneix B, Behr JP: A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo. Polyethylenimine. Proc Natl Acad Sci USA (1995) 92(16):7297-7301.
38. Zou SM, Erbacher P, Remy JS, Behr JP: Systemic linear polyethylenimine (L-PEI)-modiated gene delivery in the mouse. J Gene Med (2000) 2(2):128-134.
39. Densmore CL, Orson F, Xu B, Kinsey BM, Waldrep JC, Hue P, Bhogal B, Knight V: Aerosol delivery of robust PEI-DNA complexes for gene therapy and genetic immunization. Mol Ther (2000) 1(2):180-188.
40. Rudolph C, Schillinger U, Ortiz A, Plank C, Golas MM, Sander B, Stark H, Rosenecker J: Aerosolized nanogram quantities of plasmid DNA mediate highly efficient gene delivery to mouse airway epithelium. Mol Ther (2005) 12(3):493-501.
41. Klink DT, Chao S, Glick MC, Scanlin TF: Nuclear translocation of lactosylated Poly-L-lysine/cDNA complex in cystic fibrosis airway epithelial cells. Mol Ther (2001) 3(6):831-841.
42. Ziady AG, Kelley T, Davis PB: Molecular conjugate mediated CFTR gene transfer in CF mice affects secondary CF defects. Pediatr Pulmonol Suppl (2001) 22:254.
43. Chan CK, Senden T, Jans DA: Supramolecular structure and nuclear targeting efficiency determine the enhancement of transfection by modified polylysines. Gene Ther(2000) 7(19):1690-1697.
44. Sandgren S, Cheng F, Belting M: Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide. J Biol Chem (2002) 277(41):38877-38883.
45. Glover DJ, Lipps HJ, Jens DA: Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet (2005) 6(4):299-310.
46. Yew NS: Controlling the kinetics of transgene expression by plasmid design. Adv Drug Deliv Rev (2005) 67(5):769-780.
47. Gardlik R, Palffy R, Hodosy J, Lukacs J, Turna J, Celec P: Vectors and delivery systems in gone therapy. Med Sci Monit (2005) 11(4):RA110-RA121.
48. Chalberg TW, Genise HL, Vollrath D, Calos MP: φC31 integrase confers genomic integration and long-term transgene expression in rat retina. Invest Ophthalmol Vis Sci (2005) 46(6):2140-2146.
49. Held PK, Olivares EC, Aguilar CP, Finegold M, Calos MP, Grompe M: In vivo correction of murine hereditary tyrosinemia type I by φC31 integrase-mediated gene delivery. Mol Ther (2005) 11(3):399-408.
50. Quenneville SP, Chapdelaine P, Rousseau J, Beaulieu J, Caron NJ, Skuk D, Mills P, Olivares EC, Calos MP, Tremblay JP: Nucleofection of muscle-derived stem cells and myoblasts with φC31 integrase: Stable expression of a full-length-dystrophin fusion gene by human myoblasts. Mol Ther (2004) 10(4):679-687.
51. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, Jamieson AC, Porteus MH, Gregory PD, Holmes MC: Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature (2005) 435(7042):646-651.
52. Kircheis R, Blessing T, Brunner S, Wightman L, Wagner E: Tumor Targeting with surface-shielded ligand-polycation DNA complexes. J Control Release (2001) 72(1-3):165-170.